Skip to content
lifestyle.brickvest.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Invivyd
Invivyd Announces REVOLUTION Program Progress and Advancement of Novel, Potential First- and Best-in-Class Measles Monoclonal Antibody Candidate VMS063 for Treatment and Prevention of Measles
May 21, 2026
Invivyd Launches “Antibodies for Any Body” in Partnership with World Champion Skier Lindsey Vonn to Inspire Actions that Help Support Immune Health
May 20, 2026
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 20, 2026
Invivyd Announces Presentation at the World Vaccine Congress Washington
May 19, 2026
Invivyd Aligns with the U.S. FDA on LIBERTY, a Phase 3 Trial to Evaluate the Safety of VYD2311 Antibody Versus mRNA COVID Vaccine, and to Characterize the Safety and Immunology of Antibody and Vaccine Co-Administration
February 3, 2026
Invivyd Announces Partnership with World Champion Skier Lindsey Vonn to Educate Americans on Antibodies and Disease Prevention
January 22, 2026
Invivyd and SPEAR Study Group Announce Plan for Phase 2 Study of VYD2311 for Treatment of Long COVID and COVID Vaccine-Injured Individuals to Commence Mid-2026
January 20, 2026
←
Previous Page
1
2